New informative research on Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 2020 | Major Players: Orange County Hair Restoration…

This industry research presents the Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market size, historical breakdown data (2014 2019) and forecast (2020 2025). This report provides the estimation of market size and volume. Both top-down and bottom-up approaches have been used to estimate and validate the market size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Market study on the global market will encompass the entire ecosystem of the industry, covering five major regionsand the major countries falling under those regions.

Download Exclusive Free Sample PDF Report at https://inforgrowth.com/sample-request/5930924/stem-cell-and-platelet-rich-plasma-prp-alopecia-th

Following Top Key players are profiled in the report:Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, Virginia Surgical Center, Hair Transplant Institute of Miami, Colorado Surgical Center & Hair Institute.

The Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market report analyzes and researches the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development status and forecast in United States, EU, Japan, China, India and Southeast Asia.

Market Segmentation:

The Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market report focuses on global major leading industry players providing information such as company profiles, product picture, and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis are also carried out.

On the basis of products, the report split into: Platelet Rich Plasma Injections, Stem Cell Therapy

On the basis of the end users/applications:Dermatology Clinics, Hospitals

Get Special Discount Up To 50%,https://inforgrowth.com/discount/5930924/stem-cell-and-platelet-rich-plasma-prp-alopecia-th

Key Stakeholders as per this report are Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Manufacturers, Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Distributors/Traders/Wholesalers, Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Subcomponent Manufacturers, Industry Association, Downstream Vendors.

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects are assessed and overall research conclusions offered.

With the tables and figures, theStem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Furthermore, this Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market study will help our clients solve the following issues:

This study will address some of the most critical questions which are listed below:

Get Complete TOC: https://inforgrowth.com/enquiry/5930924/stem-cell-and-platelet-rich-plasma-prp-alopecia-th

Contact Us: Contact Person: Rohan S. Email:[emailprotected] Call: US: +1-909-329-2808 UK: +44-203-743-1890

Read more from the original source:

New informative research on Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 2020 | Major Players: Orange County Hair Restoration...

From Germany with love: Alfie, four, meets his stem cell saviour – Express

Alfie Commons and mum Lorna, 40, met Christin Bouvier, 34, for the first time on Wednesday after spending more than two years communicating via anonymous letters due to donation laws.

Alfie, from Toton, Notts, was diagnosed with acute lymphoblastic leukaemia (ALL) at seven months after he had a cold for six weeks.

After chemotherapy failed, Alfie was put on a trial immunotherapy drug which helped him to recover to be eligible for a stem cell transplant.

Unable to find a family match, his family found Christin on a worldwide register operated by blood cancer charity DKMS. She donated her cells in a one-hour op and they were flown to the UK and slowly passed into Alfies body in August 2016.

When the teacher, from Schwerin, Germany, was finally allowed to meet the family at Chiswick Town Hall in west London, the little boy gave a gift of Lacoste Pink perfume.

Mum-of-two Lorna, who works in HR, said: The meet-up was just amazing, it was everything we could have possibly dreamed of there were lots of hugs and tears.

It didnt feel like I was meeting her for the first time because wed been chatting for so long before.

As a family, we owe so much to Christin, words of thanks will never feel enough.

Christin just cried when she heard the recipient was a baby. She said: After I donated my bone marrow and the anaesthetic wore off, I called DKMS.

They told me that Alfie was a small baby and living in the UK but couldnt tell me any more due to the laws. When I found out Alfie was responding to treatment, so many tears of joy ran down my face. I still cant describe that moment.

Its a moment that is always with me. Whenever I feel a bit down, I think back to it as it always brings me so much happiness! She added that the meeting was so amazing. I was very nervous and shaking at first and when we finally met we cried a lot and hugged.

Alfie was shy at first but after a bit of time he became more comfortable and we played with some balloons and had a slice of cake.

After the transplant, Alfie developed a deadly immune condition, but this was controlled by medication. He was given the cancer all-clear in 2017 and has started school.

Lorna added: I just want more people to sign up to become donors theres a match for everyone.

Originally posted here:

From Germany with love: Alfie, four, meets his stem cell saviour - Express

BEGEV Salvage Regimen Linked to High Complete Remission Rates – Cancer Therapy Advisor

Previous research has suggested that patients with classical Hodgkin lymphoma who are refractory to or relapse after first-line therapy may be more likely to be cured after receiving second-line salvage chemotherapy followed by autologous stem cell transplantation (ASCT) than after receiving standard-dose chemotherapy.1,2 High complete remission rates prior to ASCT have been shown to predict better long-term outcomes for patients with the condition.3 Researchers have investigated a number of combination therapy regimens as induction regimens prior to ASCT for refractory to or relapsed lymphoma, yielding pre-ASCT CR rates ranging from 20% to 54% and overall response rates (ORRs) of 60% to 80%.4

A prospective multicenter single-arm phase 2 study also indicated that the combination of bendamustine, gemcitabine, and vinorelbine (BEGEV) as second-line chemotherapy before ASCT, in 59 patients with relapsed/refractory (R/R) classical Hodgkin lymphoma, resulted in a CR of 73% and ORR of 83%.5

Now, updated 5-year results from that same study have confirmed the benefits, showing a CR rate of 75% and ORR of 83%.6 But experts cautioned that a randomized trial would be needed to determine whether the regimen is superior to other treatments.

The update[d] 5-year results ofBEGEV (bendamustine, gemcitabine, vinorelbine) followed by autologous stem celltransplantation in patients with Hodgkin disease refractory or relapsing tofirst-line therapy confirm the significant data in terms of CR rate (75%) aswell as PFS (59%) and overall survival (78%), lead study author ArmandoSantoro, MD, director of the Cancer Center at Humanitas Research Hospital,Milan, said in an email.

The trial involved 27 patientswith classical Hodgkin lymphoma who were refractory to and 32 patients whorelapsed after receiving 1 line of chemotherapy. The patients received 800 mg/mgemcitabine on days 1 and 4, 20 mg/ m vinorelbine on day 1, and 90 mg/mbendamustine on days 2 and 3. The patients received 100 mg prednisolone on days1 to 4. They were given 4 cycles of BEGEV every 21 days.

Those patients who experiencedcomplete response or partial response after completing the 4 cycles receivedmyeloablative therapy with carmustine, etoposide, cytarabine and melphalan orfotemustine, etoposide, cytarabine and melphalan, which preceded the reinfusionof CD341 cells.

The researchers evaluated diseaseresponses before and after the fourth BEGEV cycle using computed tomography and18F-fluorodeoxyglucosepositron emission tomography scans accordingto the International Working Group response criteria.

The treatment prompted CR in 44patients (75%) and partial response (PR) in 5 (8%), yielding an OR of 83%. Theauthors noted that the CR rate was higher than the 54% CR rate previouslyreported for the ifosfamide, gemcitabine, vinorelbine, and prednisolone (IGEV)regimen as well as other second-line chemotherapy-based salvage regimens.

Of 49 patients who responded toBEGEV and were eligible for ASCT, 43 ended up receiving transplants. After 5years following BEGEV treatment, the PFS for all series was 59% and OS was 78%.More than 90% of patients were at high risk for relapse post-ASCT. At 5 years,33 patients who received transplants experienced continuous CR, 7 relapsed, and3 died due to unrelated factors that included pneumonia, infection, andmultiorgan failure.

View post:

BEGEV Salvage Regimen Linked to High Complete Remission Rates - Cancer Therapy Advisor

Why stem cells could be the medical innovation of the century – World Economic Forum

Right now, your bodys stem cells are working hard replacing your skin every two weeks, creating new red and white blood cells and completing thousands of other tasks essential to life. They are your own personalized fountain of youth.

Scientists generally agree that a stem cell should be able to do both of the following:

One theory of ageing suggests that between the ages of 30 and 50, our stem cells reach a turning point and start to decline in number and function. This results in the typical features associated with ageing.

There does not seem to be a single discoverer of stem cells. Accounts date back to the 1800s and even further, but the first successful medical procedure was a bone marrow transfusion in 1939. Advances in immunology led to donor matching, initially via siblings and close relatives. Unrelated donor matching flourished in the 1970s, alongside donor registries.

In the 1980s, scientists identified embryonic stem cells in mice, leading to the 1997 cloning of Dolly the Sheep. This created immense interest for human and medical applications and a backlash in the US as federal R&D funding was essentially halted in 2001.

In 2012, a Nobel Prize was awarded for the earlier discovery of induced pluripotent stem cells (iPS). Essentially, they return potency and self-renewal properties to mature non-stem cells, essentially making them act like stem cells again.

In the decade between 2010 and 2019, the first wave of stem cell start-ups emerged, alongside R&D programmes at many large pharmaceutical companies, leading to innovation and the first human clinical trials for iPS and other related therapies.

According to Q3 2019 data from the Alliance for Regenerative Medicine, there are 959 regenerative medicine companies worldwide sponsoring 1,052 active clinical trials; 525 of these companies are in North America, 233 in Europe and Israel, and 166 in Asia. In aggregate, $7.4 billion has been invested in regenerative medicine companies in 2019; $5.6 billion of which has been dedicated to gene and gene-modified cell therapy, $3.3 billion in cell therapy, and $114 million in tissue engineering.

Overview of the cancer stem cells market

Perhaps most excitingly, curative therapies are hitting the market and the results are astonishing: 60% of Acute Lymphoblastic Leukemia patients taking Novartis Kymirah showed a complete response (no traces of cancer) and were declared in full remission. Meanwhile, 75% of patients with Transfusion-Dependent -Thalassaemia treated with bluebird bios Zynteglo achieved independence from transfusions. Perhaps most astonishingly, 93% of spinal muscular atrophy patients treated with Novartis Zolgensma were alive without permanent ventilation 24 months after treatment. We should expect more medical breakthroughs in the coming years.

New science, new start-ups: several companies in the sector have gone public or been acquired. These exits led to the recycling of talent and capital into new companies. Because the science and commercial systems have also advanced, the companies in the next wave are pursuing bigger challenges, driving innovation, with even greater resources.

Patients are eager: the current market for stem cell therapies is growing at 36% per year, though it will rapidly expand when a breakthrough occurs toward the treatment of a non-communicable disease (such as cancer, diabetes, heart disease) or a lifestyle factor (for example, growing hair in the correct places, expanding cognitive abilities or increasing healthy lifespan).

New R&D models: funding is flowing into the sector from large companies, VC funds, and institutions such as the California Institute for Regenerative Medicine (CIRM) and New York State Stem Cell Science programme (NYSTEM). Some of the leading university R&D platforms include the Center for the Commercialization of Regenerative Medicine in Toronto, the Stanford Institute for Stem Cell Biology and Regenerative Medicine, the Oxford Stem Cell Institute, and most notably, the Harvard Stem Cell Institute (HSCI).

Founded in 2004, HSCI has established a phenomenal track record. It provided the first $200,000 in funding to Derrick Rossis lab, which inspired the largest biotech IPO to date. HSCI scientists were also co-founders or principals in the three most prominent gene-editing companies (CRISPR Tx, Intellia and Editas), the combined $1.55-billion True North/iPierian acquisitions and the recent $950-million acquisition of Semma Tx, Frequency Tx, Fate Tx, Epizyme Inc., and Magenta Tx.

For the casual investor, Evercore ISI is building a Regenerative Medicine Index, which may be the simplest way to build a portfolio. For institutions and those with deeper pockets, regenerative medicine funds are forming, including the Boston-centric Hexagon Regenerative Medicine Fund, which aims to create companies out of the Harvard Stem Cell Institute.

Caveat emptor. Though patients needs are immediate, those seeking treatments should think very carefully about the risks. There are many dubious clinics touting expensive stem cell treatments and some patients have experienced horrifying complications. Dr. Paul Knoepfler of UC-Davis has written a practical and scientifically accurate guide, a strongly recommended read if you or a family member are considering treatment or a clinical trial.

The leading causes of death in 1900 were mostly infectious/communicable diseases. While the prevalence of most causes has diminished, the largest increases include heart disease (+40%) and cancer (+300%). Granted, this is partly due to doubling life expectancy and a lack of death from other causes. However, given time and resources, scientists and physicians may cure these challenging diseases.

Total disease burden by disease or injury

Today, six of the seven leading causes of death are non-communicable diseases (heart disease, stroke, lung diseases, cancer, Alzheimers disease and diabetes). Based on the early promise mentioned above, regenerative medicine may be our best hope to solve the great non-communicable diseases of our time, and perhaps the single most transformative medical innovation in a century.

License and Republishing

World Economic Forum articles may be republished in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

More:

Why stem cells could be the medical innovation of the century - World Economic Forum

Stem Cell Therapy for Dogs and Cats Is Innovative at Stafford Veterinary Hospital – By MARIA SCANDALE – The SandPaper

Stafford Township, NJ Stem cell therapy is an incredible process for healing damaged tissue, so it seems remarkable that it is availablefor petsright here in Manahawkin. Stafford Veterinary Hospital, at 211 North Main St., began offering the advanced treatment in 2019, under the direction of Michael Pride, medical director at the facility.

There, stem cell therapy is most commonly applied to osteoarthritis, but can also be used in dogs suffering from hip dysplasia and ligament and cartilage injuries, as well as mobility ailments and some chronic inflammatory issues such as inflammatory bowel disease and chronic kidney disease, which is common in cats.

Stem cell therapy is actually the only thing that can help to reverse the process of arthritis, Pride said. Everything else is a Band-Aid.

This process can actually help to rebuild cartilage and really reduce inflammation without the need of using aspirin-type medications, Pride said. Its a newer technology that we can use to avoid chronic use of medications, which might actually be detrimental in the long term for the liver or kidneys.

Stem cell therapy treats the source of the problem by offering the ability to replace damaged cells with new ones, instructs the website staffordvet.com.

Stem cells are powerful healing cells in the pets body that can become other types of cells. For example, in the case of arthritis, stem cells can become new cartilage cells and have natural anti-inflammatory properties, thus reducing pain and increasing mobility.

The stem cells are your primary structural cell for all other cells in the body; they can differentiate into almost any other cell, explained Pride. Were processing it down into that primordial stem cell; were activating it, and were injecting it into where it needs to be, and it just starts taking on the characteristics of the cells around it.

Table-top machines from MediVet Biologics are the first Adipose Stem Cell therapy kits for in-clinic use, a major advancement. Stem cell therapy for animals has been commercially available since 2004. MediVet pioneered in-clinic treatment options around 2010.

Pride believes Stafford Veterinary Hospital offers the only such treatment in the immediate area; another is in Egg Harbor Township, Atlantic County.

Were always trying to figure out different ways to help the patient without hurting them, he said while petting a kitten that had been a patient for another type of treatment.

As stem cell therapy is more in the news regarding humans, a pet owners first question might be where the stem cells come from that are used in the process. The answer: from fat tissue of the pet itself, extracted and processed the same day.

As the therapy has been refined in the last decade, it has actually started to become a lot easier, more cost-effective more recently, said Pride, since weve been able to process fat tissue instead of actually getting bone marrow.

Fat tissue actually has a much higher concentration of adult stem cells than bone marrow does, so its less painful for the patient, they heal a lot easier, and we dont have to process it in a different facility.

Everything comes from the animal, and we give it back to the animal. Nothing comes from another animal. We dont have to worry about them rejecting the sample; its their own tissue, and were giving it back to them.

The pet typically goes home the same day after about eight hours. First, X-rays and a consultation with the veterinarian can determine whether the pet is a candidate for the treatment.

A pet owner may not even know that their animal has arthritis.

Cats have a lot of inflammatory issues that they tend to be very good at hiding, said Pride. A lot of people dont realize that they have arthritis. They think, oh, my cats just getting older; hes not jumping as much; hes not as strong; hes just sleeping most of the day, but actually he has arthritis. Its very difficult to diagnose in cats. A lot of times you end up having to do X-rays to find where the arthritic joints happen to be.

An inch-and-a-half incision is the minor surgery that harvests the fat tissue from the belly while the pet is anesthetized. For a cat, about 20 gramsare extracted. For a large dog, about 40 gramsare needed. While the pet is recovering from the incision surgery, the veterinary hospital is processing the sample. When the sample is ready, the pet is sedated because we then have to give them the joint injections. Then we can reverse the sedation, and they go home.

We asked the doctor if the process always works. He gave the example that on average, a dog such as a boxer that was hobbled is now able to walk without seeming like its painful. In an extreme positive case, a dog that had been barely walking might be bouncing all over the place in two months.

It doesnt always work to the extent that we would love it to, but we usually notice that there is a positive effect from it, Pride remarked. Every patient will be different in what they experience.

For the same reason that everyones situation is going to be different, cost of treatment was not given for this story.

It generally takes about 30 to 60 days for relief to show, the veterinarian said, and the animals progress will be monitored.

On average, results last about 18 months to two years before more stem cells might have to be injected. The procedure takes about an hour.

The nice thing is once we collect those stem cells (from the first procedure), we can bank the leftovers they are cryogenically stored at MediVet corporate headquarters in Kentucky and we dont have to go through the initial anesthetic surgery, said Pride.

Stem cell therapy is one of several innovative modalities available at Stafford Veterinary Hospital. Laser therapy, acupuncture and holistic medicine are others. Care for exotic pets is available, as is emergency pet care.

Visit the website staffordvet.com or call 609-597-7571 for more information on general and specialized services, including: vaccinations, microchipping, spayingand neutering, dental care, wellness exams, dermatology, gastrology, oncology, opthalmology, cardiology, soft-tissue surgery, ultrasound, radiography, nutrition, parasite control, boarding, laborand delivery, end-of-life care, and cremation.

Stafford Veterinary Hospital has been in business since 1965, founded by Dr. John Hauge. Today, five highly skilled veterinarians are on staff, and a satellite, Tuckerton Veterinary Clinic, is at 500 North Green St. in Tuckerton.

Pride has been medical director at Stafford Veterinary Hospital since 2008. He attended Rutgers University, then earned his Veterinary of Medicine degree at Oklahoma State University.

The mild-mannered doctor feels a great rewardfrom treating animals that cant speak for themselves when they feel bad.

These guys, theyre always thankful; you can see what they think, he said of treated pets. The turnaround in their attitude, the turnaround in their ability to be more comfortable, you can see it in their faces; you can see it in their actions. You learn to read animals over time.

Its knowing that were helping those who cant help themselves, he added, and you can see it in them; thats the most gratifying.

mariascandale@thesandpaper.net

Read this article:

Stem Cell Therapy for Dogs and Cats Is Innovative at Stafford Veterinary Hospital - By MARIA SCANDALE - The SandPaper

Animal Stem Cell Therapy Market Poised to Garner Maximum Revenues During 2017 2025 Dagoretti News – Dagoretti News

Latest Report on the Animal Stem Cell Therapy Market

Persistence Market Research (PMR) recently published a market study that offers critical insights related to the growth prospects of the Animal Stem Cell Therapy Market during the forecast period 2017 2025. The report takes into account the historical and current market trends to evaluate the top factors that are likely to influence the growth of the market in the upcoming years.

As per the report, the Animal Stem Cell Therapy Market is poised to grow at a CAGR of ~XX% during the assessment period primarily driven by a growing focus on product innovation, a surge in demand for the Animal Stem Cell Therapy in the developed regions, and potential opportunities in the developing regions.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/14941

Essential findings of the report:

The report aims to address the following queries related to the Animal Stem Cell Therapy Market:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/14941

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/14941

What Sets Us Apart From the Rest?

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:Persistence Market Research305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751

Original post:

Animal Stem Cell Therapy Market Poised to Garner Maximum Revenues During 2017 2025 Dagoretti News - Dagoretti News

Stem cell agency indirectly boosted by national industry group – Capitol Weekly

News

by DAVID JENSEN posted 01.13.2020

One of the nations leading regenerative medicine industry groups is touting multi-billion dollar savings that may be achieved with the type of stem cell and gene therapies that are being developed with cash from Californias financially beleaguered stem cell program.

The industry group is the Washington, D.C-based Alliance for Regenerative Medicine (ARM). It is tackling one of the major issues facing development of commercial stem cell therapies sticker shock at their expected prices, running upwards of a $1 million or more.

The ARM study predicted cost savings of as much as $33.6 billion over about a decade in connection with three afflictions: sickle cell disease (SCD),multiple myeloma (MM) andhemophilia A (Hem A).

Without a willingness from health care insurers to cover the costs and provide a pathway to profit, it is unlikely that the biotech industry will embrace production of the therapies.

In a study released Friday, the group said:

Advances in molecular biology and genetics are leading to new treatments for rare diseases that require new ways of assessing value. CGTs (cell and gene therapies) are directed at the underlying cause of a condition and offer durable, potentially curative, or near-curative benefits. These transformative therapies create challenges for current reimbursement frameworks as they (the therapies) require significant upfront costs but are expected to provide a lifetime of benefits. The recurring treatment costs of chronically-managed patients can be greatly reduced and even eliminated with a one-time administration or short course of these novel therapies.

As CGTs arrive on the market, payers need new models for assessing their value. These treatments could potentially end the patients burden of illness, resulting in cost offsets (eliminating or reducing the need for long-term treatment, hospitalizations, and other care) and productivity gains that span a lifetime. Manufacturers incur a high per-patient development cost for these therapies and payers who bear the cost of treatment may not realize the long-term financial benefits due to health plan switching.

The ARM study predicted cost savings of as much as $33.6 billion over about a decade in connection with three afflictions: sickle cell disease (SCD), multiple myeloma (MM) and hemophilia A (Hem A).

The discussion of the costs of stem cell therapies has special resonance in the Golden State where voters are likely to be asked next fall to give $5.5 billion more to its stem cell agency.

Californias stem cell agency was not mentioned in the study, but it has funded research in all three areas. The agency is a member of ARM.

The study, backed by ARM and performed bythe Marwood Group, said, Access to CGTs for even a modest number of patients with MM, SCD, and Hem A each year can reduce overall disease costs by nearly 23% over a 10-year period. The savings from lowering healthcare costs and raising productivity are considerable, approaching $34 billion by 2029. Of the savings, $31 billion are from a reduction in healthcare costs and $3 billion are from productivity gains.

The model used by ARM assumed CGT prices as high as $2 million. The study said, The model has tested more than 180 different prices across the three potential CGTs that ranged from a minimum test price of $150,000 and up to a maximum price test of $2,000,000. The prices entered into the model created 60 different cost savings curves for all three of drugs in this model. Prices were distributed with more than 50% of test prices in the $100,000-$600,000 price per administration range.

The discussion of the costs of stem cell therapies has special resonance in the Golden State where voters are likely to be asked next fall to give $5.5 billion more to its stem cell agency, known formally as theCalifornia Institute for Regenerative Medicine (CIRM).

The agency, funded with $3 billion in 2004, is down to its last $27 million. A new, proposed ballot initiative is focusing hard on affordability of stem cell treatments. The initiative has no specific solutions but stipulates that a new version of CIRM if the ballot measure is approved should devise some ways to come up with answers for insurers who are not likely to warm easily to $1 million therapies.Eds Note: DavidJensen is a retired newsman who has followed the affairs of the $3 billion California stem cell agency since 2005 via his blog, the California Stem Cell Report, where this story first appeared. He has published more than 4,000 items on California stem cell matters in the past 15 years.

Read more here:

Stem cell agency indirectly boosted by national industry group - Capitol Weekly

Study: Mutations in stem cells of young donors can be passed to recipients – STAT

Doctors use stem cell transplants to treat patients with certain cancers or blood disorders. And donors, whose blood or bone marrow is used for the procedures, are typically young, for a variety of reasons.

But a pilot study released Wednesday raised the possibility that such donors are also passing along mutations in stem cells that could lead to health problems for some recipients.

The study found that nearly 45% of younger donors had mutations in the transplanted stem cells that could raise the risk of conditions that are sometimes seen in recipients, a higher rate than presumed. Researchers also reported that some of these mutations persisted and proliferated in the recipients bone marrow for at least a year.

advertisement

What remains unknown is whether those mutations are actually contributing to health problems for recipients.

The study was small, with just 25 donors included and was not large enough and did not last long enough to determine whether people who received cells with these mutations had worse outcomes after a transplant than recipients who got cells without those mutations. Dr. Todd Druley, the senior author of the paper, which was published in the journal Science Translational Medicine, emphasized that patients should continue to receive these stem cells to treat their leukemias or anemias when recommended.

What were trying to say is that now we can provide surveillance before, during, and after a bone marrow transplant so that if theres an increased risk for a particular outcome, treatment for that and surveillance for that can be instituted sooner, said Druley, a pediatric oncologist at Washington University in St. Louis.

Researchers not involved with the study praised its technical prowess, and said it was worth investigating further to see if the transplanted mutations did lead to worse outcomes for recipients projects that Druley and his colleagues have underway. But they agreed it should not yet change clinical practice.

Donors are already screened to make sure they have a clean bill of health and make for a good match for recipients, based on their immune systems. Experts said it would be unrealistic to screen every potential donor for the kinds of mutations Druley and his team found. Those mutations were infrequent, and it wasnt clear they posed health risks to recipients.

We know that younger donors are better than older donors. We know that the better the donor the better the outcomes. We dont know how these ultra-low level mutations affect outcomes at all, said Dr. Corey Cutler, the medical director of the adult stem cell transplantation program at Dana-Farber Cancer Institute.

Hematopoietic stem cells generate blood and immune cells. They are sometimes transplanted into patients with certain blood or immune disorders or cancers whose own cells have been wiped out by chemotherapy, essentially restocking the recipients with healthy cells.

But recipients of these transplants sometimes experience graft versus host disease (when the transplant attacks the recipients tissues), heart or immune conditions, or even secondary cancers. Some experts have suspected these conditions might be caused by mutations in donor stem cells, among other factors. Its in part why they favor younger donors, who are expected to have fewer mutations than older donors. (Donors from 18 to 44 account for 86% of transplants for unrelated patients. Relatives often make for better donors because they are more likely to be matched to recipients based on immune system molecules.)

Most of these mutations are probably benign. But its possible that other mutations not only pose a health risk, but also give their host cells a boost over other cells, helping them proliferate over time. That might mean someone who is 40 could have a bad mutation in one in 5,000 cells, but by the age of 50, it could be in one in 50 cells, Druley explained.

The challenge is detecting those mutations. Standard sequencing technology may pick up mutations if they appear in just a small percentage of cells, but for young donors, it would be like finding the few pebbles in a beach full of sand.

Next-generation sequencing is good if you want to find a mutation thats in 20% of cells youre looking at, or even 5%, Druley said. Were looking at mutations that are one in a thousand, or down to one in ten thousand.

For the new study, Druley and colleagues trained a more powerful tool they call error-corrected sequencing on the cells of the 25 donors, who ranged from 20 to 58 years old. (Fifty-eight would be considered older donors, but the median age of the donors in the study was 26.) They looked for mutations in 80 genes in particular, including genes that, when mutated, are associated with leukemia.

What they found: 11 donors had a collective 19 mutations that were not picked up by standard sequencing technology 16 of which were pathogenic, meaning disease causing.

The researchers also studied the recipients, finding that 14 of the 19 mutations had engrafted, or been taken up by the recipient and started to generate other cells, and were still there a year after the transplant. Thirteen of these mutations were pathogenic.

Researchers said it made sense that younger adults had these types of mutations, even if scientists hadnt previously been able to spot them.

Its known that mutations accumulate over time, said Dr. Ross Levine, a leukemia specialist at Memorial Sloan Kettering Cancer Center, who was not involved in the new study. The question has always been in other scenarios if you can detect these clones at earlier or in different contexts, and if they mean anything.

The new study was not set up to answer that last question.

Thats the next phase of this research, Druley said. Some of these mutations, if theyre going to have an effect, may not have an effect for many, many years. And we had a small population. So we didnt have enough numbers or enough time.

Outside researchers said that if these stem cell mutations do contribute to diseases once transferred to recipients, it might take so long or happen so infrequently that it would be difficult to study. Dana-Farbers Cutler said that, for example, cases of donor-derived leukemia when the recipient develops blood cancer after a transplant occur in less than 1% of transplants from unrelated donors.

If the mutations do increase the likelihood of complications in recipients, then why arent they posing a problem for the donors themselves? That might also be tied to the prevalence of these mutations, the researchers said.

In donors, these mutations might appear in, say, 1% of cells, and there is competition among cells of all different types of genetic variants to multiply. Plus, donors have healthy immune systems that can help suppress bad actors.

But if cells with these mutations make their way into recipients who have had their own cells blasted away with chemotherapy, its a new race. The mutations might give them some advantage to multiply faster than other cells that were transplanted. And as the percentage of cells with these mutations rises, they might be more likely to cause disease.

When you have these mutations in a host, it may take decades for them to expand to the point of causing issues, Levine said. In a recipient, however, its almost like youve reset the playing field.

Continued here:

Study: Mutations in stem cells of young donors can be passed to recipients - STAT

Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) Dagoretti News – Dagoretti News

obal Cell Therapy Technologies Marketwas valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/31531

Global Cell Therapy Technologies Market: OverviewCell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

Global Cell Therapy Technologies Market: Drivers and RestraintsThe growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation AnalysisOn the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional AnalysisNorth America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

Do Inquiry Before Purchasing Report Here:https://www.maximizemarketresearch.com/inquiry-before-buying/31531

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & SoftwareGlobal Cell Therapy Technologies Market, by Cell Type

Human Cells Animal CellsGlobal Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality ControlGlobal Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research InstitutesGlobal Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at:https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

See original here:

Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) Dagoretti News - Dagoretti News

Muscular dystrophy collaboration aims to correct muscle stem cells’ DNA – Harvard Office of Technology Development

All News

January 13, 2020

We expect that a satellite cell with the corrected DMD gene would quite quickly and continuously propagate the edited gene throughout the muscle tissue, said Prof. Amy Wagers, who leads the research. (Photo credit: Jon Chase/Harvard Staff Photographer.)

Cambridge, Mass. January 13, 2020 Harvard University stem cell researchers led by Amy Wagers, PhD, are embarking on a major study of Duchenne muscular dystrophy (DMD). Supported by research funding from Sarepta Therapeutics, under a multi-year collaboration agreement coordinated by Harvards Office of Technology Development (OTD), the project aims to use in-vivo genome editing, in mouse models of DMD, to fully and precisely restore the function of the dystrophin protein, which is crucial for proper muscular growth and development. Approaches validated by this work may point the way to an eventual therapeutic strategy to reverse DMD in humans.

Duchenne muscular dystrophy is a genetic disease caused by the lack of a protein called dystrophin that normally helps to support the structural integrity of muscle fibers, including those in the heart. Without the dystrophin protein, cells are weaker and degenerate more quickly. Over time, affected individuals boys, typically, as it is a recessive X-linked disorder lose their capacity to move independently.

Its really a devastating disease; it robs young boys of their capacity to be young boys, said Wagers, who is the Forst Family Professor of Stem Cell and Regenerative Biology, Co-Chair of the Department of Stem Cell & Regenerative Biology, and an Executive Committee Member of Harvard Stem Cell Institute. Though it is early days, Im hopeful that through this work we may identify and validate new avenues for therapy to completely rescue the proper expression and function of the dystrophin protein and regenerate healthy muscle tissue.

Researchers worldwide have pursued a variety of promising approaches such as cell and gene therapies, small-molecule therapies, and others to lessen or prevent the disease and improve patients quality of life.

The strategy pursued by the Wagers Lab at Harvard aims to fully correct the genetic template for dystrophin at its source, in the DNA of stem cells (satellite cells) that create and regenerate muscle cells. Combining cutting-edge CRISPR/Cas9 genome editing technologies with a deep knowledge of stem cell science and regenerative biology, this approach if successful might offer a permanent restoration of muscular function.

In skeletal muscle, muscle fibers are terminally post-mitotic, meaning they cannot divide and they cannot reproduce themselves, Wagers explains. If you lose muscle fibers, the only way to produce new muscle is from stem cells, specifically the satellite cells. The satellite cells are self-renewing, self-repairing, and ready to spring into action to create new muscle fibers. So we expect that a satellite cell with the corrected DMD gene would quite quickly and continuously propagate the edited gene throughout the muscle tissue.

At present, research conducted in mice has shown promising results. In June, the Wagers Lab published the results of editing stem cells in vivo, demonstrating that stem cell genes can be edited in living systems, not only in a dish. In that work, Wagers and her team delivered genome editing molecules to the cells using adeno-associated viruses (AAVs). Her lab has also successfully used gene editing in heart, muscle, and satellite cells to partially restore the function of the DMD gene that encodes dystrophin, by chopping out faulty sequences of code that are disrupting the proper reading frame.

The new stem-cell approach pursued in collaboration with Sarepta would build on these achievements and use more precise genome editing approaches, in animal models of DMD, to entirely replace genetic mutations in the DMD gene with correctly encoded sequences. The project will also explore alternate delivery methods and strategies to mitigate immune effects of in vivo genome editing.

This ambitious project will benefit greatly from the resources and insights of a company with deep clinical experience in the development of therapeutics for muscular dystrophy, said Vivian Berlin, Managing Director of Strategic Partnerships at Harvard OTD. Preclinical discoveries by Harvard researchers may open entirely new possibilities for lifesaving treatments in the long run, offering much-needed hope to patients and families in the future. Were grateful to be able to sustain the important momentum already established in Prof. Wagers lab, through this collaboration.

As we work to bring forward new treatments for patients with DMD, Sarepta is excited to support Prof. Wagers and her lab to accelerate the development of a gene editing approach, which has shown significant potential in early studies, said Louise Rodino-Klapac, Sareptas Senior Vice President of Gene Therapy. This multi-year collaboration is part of Sareptas broader commitment to pursuing all therapeutic modalities and advancing our scientific understanding of gene editing in order to maximize the potential of this approach to help patients.

Under the terms of the agreement between Harvard and Sarepta, the company will have the exclusive option to license any arising intellectual property for the purpose of developing products to prevent and treat human disease. As with any research agreement facilitated by OTD, the right of academic and other not-for-profit researchers to use the technology in further scholarly work is preserved.

All News

View original post here:

Muscular dystrophy collaboration aims to correct muscle stem cells' DNA - Harvard Office of Technology Development

The Clinical Trial that MS Patients Have Been Waiting For – Multiple Sclerosis News Today

People with multiple sclerosis have been waiting for this: A full-scale clinical trial testing the effectiveness of stem cell transplantation as an MS treatment. The trial is being conducted by the U.S. National Institutes of Health, and its enrolling people with MSat several centers in the United States and one in the United Kingdom.

The U.S. has been behind the curve when it comes to approving stem cell treatments for people with MS. Autologous hematopoietic stem cell transplantation (aHSCT) has been available in Mexico and Russia for several years, but isnt widely available in the U.S.

In the procedure, doctors collect a patients blood-forming stem cells, give the patient high-dose chemotherapy to deplete the immune system, and then return the patients own stem cells to rebuild the immune system. The system, hopefully, returns free of cells believed to be involved with MS.

Three years ago, following a promising aHSCT study, Dr. Anthony Fauci was optimistic but cautious. Fauci is the director of the National Institute of Allergy and Infectious Diseases. He said, These extended findings suggest that one-time treatment with HDIT/HCT may be substantially more effective than long-term treatment with the best available medications for people with a certain type of MS. But Fauci emphasized that a larger trial was still necessary. It appears that trial has finally arrived.

The Phase 3 trial, called BEAT-MS (NCT04047628), will put aHSCT head-to-head against the top-line disease-modifying therapies (DMTs) available in the U.S. to treat MS.

It will enroll 156 adults, ages 18 to 55, with a diagnosis of relapsing-remitting MS (RRMS) at 21 sites 20 in the U.S. and one in the U.K. Participants will be randomly assigned to receive either aHSCT or one of the high-efficacy MS treatments currently in use: Ocrevus (ocrelizumab), Lemtrada/Campath (alemtuzumab), Tysabri (natalizumab), or Rituxan (rituximab). The participants, who wont know which treatment theyre receiving, will be followed for six years.

In a news release, investigators said they want to compare how much time elapses between the start of the treatment and an MS relapse. Theyll also compare the newly developing immune systems of the participants who receive aHSCT with the immune systems of those who receive a DMT.

Finally, theyll compare the effects of the two treatment types on other measures of disease activity and severity, their cost-effectiveness in terms of healthcare costs and productivity, and participants quality of life. We hope that BEAT-MS will clarify the best way to treat people with relapsing MS, said Dr. Jeffrey Cohen, the trials leader.

I hope so, too. A study such as this is long overdue. But I think I echo the feelings of many people with MS when I express dismay that were probably still at least six years away from approval of aHSCT in the U.S.

As I wrote three years ago, [S]cientists have been studying stem cell treatments for years and it sure seems as if were still crawling when we should be cruising. Also, why limit this study to people with RRMS? Why not include those with primary and secondary progressive MS? Am I wrong to think that they would benefit from aHSCT as much, if not more, as those with relapsing MS?

What do you think?

Starting this month, Multiple Sclerosis News Today columnist Jennifer Powell and I have begun recording MS news and feature stories in audio format. Jennifers audio reports are available on SoundCloud every Monday, and mine are available every Thursday. Click here to give us a listen.

Youre invited to visit my personal blog at http://www.themswire.com.

***

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.

Ed Tobias is a retired broadcast journalist. Most of his 40+ year career was spent as a manager with the Associated Press in Washington, DC. Tobias was diagnosed with Multiple Sclerosis in 1980 but he continued to work, full-time, meeting interesting people and traveling to interesting places, until retiring at the end of 2012.

See the article here:

The Clinical Trial that MS Patients Have Been Waiting For - Multiple Sclerosis News Today

Novel form of cell-free therapy revealed by researchers – Drug Target Review

Researchers have developed cytochalasin B-induced membrane vesicles which they suggest could be a new form of cell-free therapy in regenerative medicine.

Work on extracellular microvesicles (ECMVs) derived from human mesenchymal stem cells (MSCs) has revealed a potential new form of cell-free therapy.

ECMVs are microstructures surrounded by a cytoplasm membrane; they have proven to be a prospective therapeutic tool in regenerative medicine due to their biocompatibility, miniature size, safety and regenerative properties. These can be used to circumvent the limitations of existing cell therapies without losing any effectiveness.

Cell therapies are grafts or implants of living tissue, such as bone marrow transplants, used to replace and regenerate damaged organ tissue. They currently have limited applications, as they work differently dependent on conditions and the environment they are placed into. They can also be rejected by the immune system.

A study at Kazan Federal University, Russia, has investigated cytochalasin B-induced membrane vesicles (CIMVs) which are also derived from MSCs and are very similar to natural ECMVs.

Proteome analysis of human MSCs and CIMVs-MSCs. Venn diagram of identified proteins MSCs and CIMVs-MSCs (A). Distribution of the identified proteins in organelles, percent of unique identified proteins (B) (credit: Kazan Federal University).

The scientists studied and characterised the biological activity of MSC-derived CIMVs. A number of biologically active molecules were found in CIMVs, such as growth factors, cytokines and chemokines; their immunophenotype was also classified.They also found that CIMVs could stimulate angiogenesis in the same way as stem cells.

The team came to the conclusion that human CIMVs-MSCs can be used for cell-free therapy of degenerative diseases. Induction of therapeutic angiogenesis is necessary for the treatment of ischemic tissue damage (eg, ischemic heart disease, hind limb ischemia, diabetic angiopathies and trophic ulcers) and neurodegenerative diseases (eg, multiple sclerosis and Alzheimers disease), as well as therapies for damage of peripheral nerves and spinal cord injury.

The group say they are continuing to research the therapeutic potential for artificial microvesicles for autoimmune diseases.

The study was published in Cells.

See the original post here:

Novel form of cell-free therapy revealed by researchers - Drug Target Review

Astellas, Adaptimmune to develop CAR-T & TCR T-cell therapies – BSA bureau

Astellas will pay Adaptimmune an upfront payment, research funding, development and commercial milestones, and royalties on net sales on co-commercialized products

Japan based Astellas Pharma Inc., through its wholly-owned subsidiary Universal Cells, Inc. and Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, have announced that they have entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.

Astellas and Adaptimmune will agree on up to three targets and co-develop T-cell therapy candidates directed to those targets. These targets will exclude target specific T-cell products in pre-clinical or clinical trials or those developed for other partners at Adaptimmune. The collaboration will leverage Adaptimmune's target identification and validation capabilities for generating target-specific T-cell Receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that recognize surface epitopes independently of the HLA profile of the tumor cell. The collaboration will also utilize Astellas Universal Donor Cell and Gene Editing Platform it obtained through the acquisition of Seattle-based Universal Cells.

Adaptimmune has been collaborating with Universal Cells since 2015 on development of gene-edited iPSC cell lines, for which Adaptimmune has rights to develop and commercialize resulting T-cell therapy products using its proprietary process for generating T cells from stem cells without the use of feeder cell lines.

Astellas will fund research up until completion of a Phase 1 trial for each candidate. Upon completion of the Phase 1 trial for each candidate, Astellas and Adaptimmune will elect whether to progress with co-development and co-commercialization of the candidate, or to allow the other Party to pursue the candidate independently through a milestone and royalty bearing licence, with the agreement allowing for either company to opt out. The companies will each have a co-exclusive licence covering the co-development and co-commercialization of the product candidates within the field of T-cell therapy. If a candidate is developed by one company only, the appropriate licences will become exclusive to the continuing party.

Astellas will also have the right to select two targets and develop allogeneic cell therapy candidates independently. Astellas will have sole rights to develop and commercialize these products, subject to necessary licenses and the payment of milestones and royalties.

Under the terms of the agreement, Adaptimmune may receive up to $897.5 million in payments, including:

In addition, Adaptimmune will receive research funding of up to $7.5 million per year.

Finally, Adaptimmune would receive tiered royalties on net sales in the mid-single to mid-teen digits.

Under the terms of the agreement, Astellas may receive up to $552.5 million, including:

In addition, Astellas would receive tiered royalties on net sales in the mid-single to mid-teen digits.

To the extent that Astellas and Adaptimmune co-develop and co-commercialize any T-cell therapy, they will equally share the costs of such co-development and co-commercialization, with the resulting profits from co-commercialization also shared equally. Further details governing co-development and co-commercialization will be articulated in a product-specific commercialization agreement.

The impact of this transaction on Astellas financial results in the fiscal year ending March 31, 2020 will be limited.

Read the original post:

Astellas, Adaptimmune to develop CAR-T & TCR T-cell therapies - BSA bureau

Rheumatoid Arthritis Stem Cell Therapy Market Latest Innovations, Drivers and Industry Key Events 2018 to 2028 – Fusion Science Academy

Global Pulse Ingredients Marketwas valued at US$ 17.7 Bn in 2018 and is expected to reach US$ 28.9 Bn by 2026, at a CAGR of 6.32% during a forecast period.

Based on the type, the pulse flour segment is expected to propel the global pulse ingredients market growth in the near future as increased demand for pulse flour from food manufacturers across the globe. The rise in usage of pulse flours in the food industry to produce food products which are highly nutritious, have a low-glycemic-index, protein-fortified, and are gluten-free. On the basis of application, food & beverage segment is projected to surge the global pulse ingredients market growth during the forecast period as the growing demand for the healthy food products among consumers across the globe. In addition, increased population coupled with rising per capita income of the middle-class population in emerging economies, which is fuelling the global pulse ingredients market growth in a positive way. In terms of source, chickpea segment is estimated to surge the global pulse ingredients market growth as growing consumers inclination towards the adoption of chickpea. It has health benefits such as stabilizing blood sugar level, minimizing heart attack risk, which is also driving the global pulse ingredients market growth.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/28569

The rise in concerns regarding health and increased demand for high-quality food products among consumers across the globe, which are driving the global pulse ingredients market growth. The growing trend of chickpea flour adding as a thickening ingredient in soups across the globe. Increased technological advancements such as smart packaging are also fuelling the global pulse ingredients market growth in a positive way. Increase in consumption of bread which is made by pulse ingredients in the Asia Pacific region, which provides opportunities to the manufacturers. The rise in the trend of gluten-free vegetarian and vegan diets, which is booming the global pulse ingredients market growth.

In terms of region, the Asia Pacific is estimated to hold the largest share in the global pulse ingredients market in the forecast period as rapid urbanization and increased influence of western lifestyles among consumers. In addition, growth in popularity of convenience foods, higher per capita consumption of baked goods, and the presence of key players in this regions, which are boosting the global pulse ingredients market in a positive way. The global pulse ingredients market is driven by the growing consumption of high-protein products and consumers preference toward a vegan and vegetarian diet. Changing lifestyle is one of the key trends in the global pulse ingredients market in this region. North America is projected to generate the highest CAGR in the global pulse ingredients market during the forecast period.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Pulse Ingredients Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTERs analysis, SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in Pulse Ingredients Market.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/28569

Scope of the Report Pulse Ingredients Market

Global Pulse Ingredients Market, by Type

Pulse Flours Pulse Starch Pulse Proteins Pulse Fibers & GritsGlobal Pulse Ingredients Market, by Source

Lentils Peas Beans ChickpeasGlobal Pulse Ingredients Market, by Application

Food & Beverages Feed OthersGlobal Pulse Ingredients Market, by Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey Players Operating in Global Pulse Ingredients Market

Ingredion Roquette Frres Emsland Group The Scoular Company Archer Daniels Midland Company AGT Food and Ingredients ANCHOR INGREDIENTS. Avena Foods, Limited COSUCRA. Vestkorn Dakota Dry Bean Puris. Axiom Foods, Inc. SunOpta Batory Foods Diefenbaker Spice & Pulse.

MAJOR TOC OF THE REPORT

Chapter One: Pulse Ingredients Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Pulse Ingredients Market Competition, by Players

Chapter Four: Global Pulse Ingredients Market Size by Regions

Chapter Five: North America Pulse Ingredients Revenue by Countries

Chapter Six: Europe Pulse Ingredients Revenue by Countries

Chapter Seven: Asia-Pacific Pulse Ingredients Revenue by Countries

Chapter Eight: South America Pulse Ingredients Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Pulse Ingredients by Countries

Chapter Ten: Global Pulse Ingredients Market Segment by Type

Chapter Eleven: Global Pulse Ingredients Market Segment by Application

Chapter Twelve: Global Pulse Ingredients Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Pulse Ingredients Market Report at:https://www.maximizemarketresearch.com/market-report/global-pulse-ingredients-market/28569/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Original post:

Rheumatoid Arthritis Stem Cell Therapy Market Latest Innovations, Drivers and Industry Key Events 2018 to 2028 - Fusion Science Academy

Botox, medical drips and more offered at NVY Center – SILive.com

STATN ISLAND, N.Y. -- As a Manhattan-based attorney, Chris Cardillo has overseen his share of medical management over the years.

Paperwork involved with being a doctor is so overwhelming these days, he said, noting that many physicians turn to attorneys to help manage their practices.

So with a wide knowledge of the medical industry, he sought to open a business that would house different physicians, as well as spa services, in a medical spa setting under one roof.

The result is NVY Center, a medical management company that opened in Richmond Valley more than one year ago.

As a Manhattan-based attorney, Chris Cardillo has completed his share of medical management over the years. Paperwork involved with being a doctor is so overwhelming these days, he said, noting that many physicians turn to attorneys to help manage their practices. (Staten Island Advance/Tracey Porpora)

I became very interested in the concept because I think its the wave of the future, said Cardillo, who has several partners in the business. Almost every medical office has a medical manager. ...When you go to a hospital, like New York University Medical Center, the hospital does all the management for doctors with affiliated practices. What hospitals do for their doctors, we do on a private level.

MEDICAL, SPA SERVICES UNDER ONE ROOF

NVY Center rents a clean, white expansive space to various medical professionals, and aestheticians, who provide spa services.

We are hoping to be a national brand. What we do is solicit doctors to lease space for us and we manage them. That means when a doctor comes in here the only thing the doctor has to worry about is taking care of the patient, said Cardillo. We take care of the billing. They dont have to do any of the paperwork. Everything they need to do their job is here for them already.

Under the NVY Center roof are an array of spa services -- from stem cell therapy and IV drips to facials and aesthetic injections. (Staten Island Advance/Tracey Porpora)

MEDICAL SPA SERVICES

Under the NVY Center roof are also an array of medical spa services, from stem cell therapy and IV drips, to facials and aesthetic injections.

Included in the facilitys design are individual medical offices, rooms where different procedures, such as facials, can take place, and an IV drip chair area. And the facility always has a medical professional on the premises, said Cardillo.

We do everything from anti-hangover to anti-flu drip. ... Soon, well be able to come to your house and do an IV drip, explained Cardillo. We want this to be a one-stop-shop for modern services."

He noted the IV drips often include vitamins and are used for various purposes, including by those people who desire to lose weight.

We have fast-drips that are 15 minutes long, where we can fill you with fluids if youre not feeling good, said Cardillo. Depending on what were trying to treat, we will mix vitamins and other medicines into the IV drip. But the fluid helps no matter what.

He said the company also hosts IV drip and Botox parties.

Other services include Trusculpting," a fat reduction procedure to lose weight, and laser hair removal, said Cardillo.

NVY CENTER AT A GLANCE

Address: 236 Richmond Valley Rd.

Website: http://www.nvycenter.com

Facebook: http://www.facebook.com/nvycenter/

New Businesses in Focus is a weekly column that relates the stories of new Staten Island businesses owners.

If you have a new business on Staten Island, e-mail porpora@siadvance.com.

MORE NEW BUSINESSES IN FOCUS COLUMNS:

FOLLOW TRACEY PORPORA ON FACEBOOK and TWITTER

View original post here:

Botox, medical drips and more offered at NVY Center - SILive.com

Out of the lab and into your frying pan: the advance of cultured meat – The Guardian

I am sitting at a kitchen worktop in the airy offices of San Francisco food startup Eat JUST. As a vegetarian, Im in angst about what is being gently turned over for me in the fryer by one of the chefs. Sitting beside me, the companys CEO Josh Tetrick tries to put my moral dilemma into perspective. Youre not my target market, he says. Its people who are eating meat for breakfast, lunch and dinner.

The product in the fryer is JUSTs prototype chicken nugget, which costs about $50 to make. It is manufactured from what the industry calls cultured, cell-based or cultivated meat (though the outside world knows it more commonly as lab-grown meat). Not to be confused with meat that is plant derived, it is produced directly from animal cells with little need to raise and no need to slaughter actual animals. It is a technology with the potential to fundamentally change the world significantly replacing the way meat is produced now with a kinder and less environmentally damaging alternative.

Cultured meat is a colossal market opportunity says Bruce Friedrich, co-founder and executive director of the Good Food Institute (GFI), a nonprofit organisation that promotes cultured meat and plant-based meat. Even a tiny bite of the $1.4tn annual global meat market would be a lot.

No cultured meat products are on the market yet and nor has it been approved in any country but they are expected to begin trickling into high-end restaurants over the next couple of years. A plethora of companies are at various stages of scaling up production and several have done public and private tasting of various prototypes. They are working on everything from chicken to beef to fish and have both humans and pets in their sights.

The GFI estimates that since San Francisco Bay Area-based Memphis Meats the first startup was founded in 2015, a total of 60 enterprises now make up the market with cultured meat as their sole business focus; collectively they have raised nearly $140m in disclosed funding. That comes mostly from venture capitalists but also from agriculture multinationals such as Tyson and Cargill.

Should cultured meat be allowed to be called meat at allif it hasnt been harvested from a whole animal?

JUST, which isnt included in the GFIs figures because it also makes vegan egg and mayonnaise, announced it was pursuing cultured meat in mid-2017, though it does not disclose what proportion of the $220m-plus it has raised in funding it is directing to its cultured meat endeavours. Meanwhile regulators are working on the approvals process and labelling requirements. Tetrick says JUST is ready to release its chicken nuggets in some high-end restaurants in an Asian country as soon as it has the thumbs up from the countrys regulator, with whom it is in dialogue. Chicken is considered easier in part because the vaccine industry has been using avian stem cells to produce vaccines for years: there is existing knowledge to draw on.

Establishing this industry isnt easy, however. While companies work out technicalities, voices raising concerns about the technology and its implications are coalescing. It is also clear there is no agreed position on whether the material itself even counts as meat. Cultured meat is in a process of becoming, sums up Neil Stephens, a sociologist at Brunel University, London, who has been studying the area for over a decade and co-founded the group Cultivate to help build discussion of the technology. It might become a stable category as meat, but its not there yet.

To a certain extent, the science of culturing meat is relatively well understood. The process begins when a cell is taken from an animal and grown up in a lab to permanently establish a culture (called a cell line). The cells can come from a range of sources: biopsies of living animals, pieces of fresh meat, cell banks and even the roots of feathers, which JUST has been experimenting with. Cell lines can either be based on primary cells for example muscle or fat cells or on stem cells. Stem cells have the advantage that with different nutrients, or genetic modifications, they are able to mature into any cell type. There is also no limit to how long stem-cell lines can live, so it is possible to use them indefinitely to produce a product. Once a good cell line for example, one that grows fast and is tasty has been selected, a sample is introduced into a bioreactor, a vat of culture medium where the cells proliferate exponentially and can be harvested. The resulting meat cell mush can be formed into a plethora of unstructured items, from patties to sausages with or without other ingredients added for texture. Conventional meat has a variety of cell types from which it derives its flavour, including both muscle and fat, and the companies are trying to broadly replicate that.

JUST isnt specifying how the cell source for the particular nugget I am about to try was obtained it gets its cells in many ways but I am assured the process didnt involve any slaughter, which is why I think I am on safe ground eating it. For most people, notes Tetrick, it wont matter how the cell is obtained. It is also not disclosing whether it was grown from a primary cell or a stem-cell line (which it doesnt genetically modify). And I dont know the exact type of chicken cells in the final product.

When I do bite into the nugget which I am told is about 70% chicken, on a par with a premium chicken nugget it has a dense texture and a mild, somewhat creamy flavour that reminds me of a pressed chicken sandwich I once bit into by accident. It also contains an amount of JUSTs own mung bean protein isolate for texture along with water, oil, salt, pepper and, this being a nugget, breading.

Yet while establishing cell lines is one thing, scaling them up for mass production at a competitive price is another. The problem is that the culture medium needed for the cells to grow is expensive and animal cells can take time to proliferate. And there is no guarantee that a small operation will work at large scale.

Compounding the challenge is the need to develop good alternatives to foetal bovine serum (FBS). Derived from the blood of cow foetuses, it is often added to culture media where the growth factors it contains work their magic. But its use is a nonstarter for an industry trying to take animals out of the equation and many companies are hard at work producing their own alternatives. All of the companies have pledged that they will not sell products that involve FBS in the production, notes Friedrich.

A further aspiration of the companies is moving beyond mush. Technologies such as 3D printing and edible scaffolds may enable this and there have been early demos. But producing, say, a fillet is much more difficult than ground meat.

There is also the challenge of getting consumers over the yuck factor. Stephens notes that the people prepared to try it tend to be educated, male and young and that it is they who could help normalise it. Tetrick thinks the answer will ultimately come down to making products that are tasty and affordable and, in the early days at least, educating people about the process and the benefits, which he notes would also extend to safer products because faecal contamination would be eliminated, as would antibiotics (sterile conditions would stop bacteria and viruses taking hold, and if they did, any contaminated batches could be discarded).

For a technology with such far-reaching implications for everything from rural livelihoods to human identity, critical public discussion and debate to date have been relatively limited. But that may be changing.

The website Clean Meat Hoax was launched last year by an informal group of 16 animal rights scholars and activists. It rails against cultured meat on the grounds that it still suggests that meat is desirable, and that animals are a resource people can draw on. It contrasts with the more pragmatic position other animal rights groups such as People for the Ethical Treatment of Animals (Peta) have taken in favour of the technology on the grounds that animals lives will be saved. What is incredible to me is how uncritically this technology is being celebrated and I dont think thats an accident we dont want to consider the possibility that we can stop eating animals, says site founder John Sanbonmatsu, a philosopher at Worcester Polytechnic Institute in Massachusetts.

Meanwhile an advertisement in Brussels metro stations designed to undermine cultured meat contrasts a barn of cows surrounded by greenery to a meat lab surrounded by transmission towers. It is the work of the European Livestock Voice campaign set up last year by a number of European farming industry groups to stress the potential social impacts of upending the meat industry.

Other voices, meanwhile, dont reject the technology wholesale but have concerns over certain aspects.

What to make ofall the company founders who would be vegan if they didnt eat their ownproduce?

Michael Hansen is a senior scientist in the advocacy division of the nonprofit organisation Consumer Reports, which compares consumer products. He worries about the potential for bioreactor contamination but also wants more transparency from the companies on their science. How, for example, are they dealing with cells that spontaneously mutate? And what are the implications of the fact that immortal cell lines could, with their uncontrolled growth, be defined as cancer cell lines? He would also like to see data on how end products compare compositionally and nutritionally with the conventional versions. You would think they would put samples out for somebody to test but all we have are assertions, he says.

The environmental campaign group Friends of the Earth (FoE), meanwhile, is keeping an open mind but stresses that the technology must not distract from existing, proven solutions to helping the planet, such as reducing reliance on animal feed produced on cleared ecoregions, cutting down food waste and supporting healthier diets. It also notes that it is extremely energy intensive to produce cultured meat and that the sustainability claims made by the companies will also need proper assessment. (JUSTs facilities are currently powered by electricity from the grid, but it plans to be more energy efficient in the future).

Perhaps more significantly for the companies, there remains the question of whether cultivated meat should be allowed to be called meat at all if it hasnt been harvested from a whole animal. The United States announced last year that cell-cultured livestock and poultry products would be regulated jointly by the Food and Drug Administration and the Department of Agriculture but further detailed requirements along with labelling rules are awaited.

So far, the industry has done a good job of arguing that its products are meat. While debate continues within the cultured meat industry about exactly what adjective to put in front (clean meat was dropped because funders in the conventional meat industry didnt like the dirty connotation it gave conventional meat), the meat is a constant which asserts its claim to be either a subcategory of meat or just meat. I actually think the word meat does more work [than any of the adjectives], says Stephens. And if Tetrick has his way, using any sort of prefix wont be necessary for long. Phones were only called Smartphones at the beginning, he points out. As something normalises you drop it. At the end of the day this thing is going to be called meat.

But others dont want it to be called meat at all.

Steered by the so called barnyard lobby, which represents the meat, livestock and poultry industries, over 30 US states have considered or are considering so-called truth in labelling laws aimed at preventing words such as meat, beef or pork being used to describe cultured meat (the laws often also target plant-based products). So far, laws have been passed in 12 states. Under Louisianas new law, which takes effect later this year, meat would specifically exclude anything that was a cell-cultured food product grown in a laboratory from animal cells. While state laws will be superseded when federal labelling rules for cultured meat come in, it doubtless sends a strong message to regulators as they decide.

Yet, notes Friedrich, whose GFI is challenging various pieces of state legislation in court, the outcomes could be really bizarre if cultivated meat cannot be called meat. Some people have meat allergies Its a consumer safety issue, he says.

If meat were to removed from the name, it would be a blow to an industry that believes that being recognised as meat is the most likely way to change the world. Perhaps it is unsurprising, then, that last year cultured meat companies came together to form their own lobby group.

Meanwhile, whats a vegetarian to do where cultured meat is concerned? And what to make of the many company founders, including Tetrick, who would be vegan if they didnt eat their own products? For the UK Vegetarian Society, there isnt enough information yet to decide whether cultured meat can be considered vegetarian. There are still questions to answer, it says, adding that those questions centre on production, ingredients, provenance and ethics. In contrast, for the UK Vegan Society, it is definitively not a vegan product because the initial cells are taken from animals. We may need a new word for people who eat exclusively cultivated meat, says Friedrich.

Certainly, from what meat is to what it is to be vegetarian or vegan, cultured meat is blowing apart our existing categorisations. Meat cell product, anyone?

Cats and dogs consume more than 25% of the US meat supply. Pet food company Because Animals wants to see those diets replaced with meat grown in the lab. Pet food has a huge environmental footprint, says Shannon Falconer, co-founder and CEO. The company plans to launch a mouse meat cat treat made of 10% mouse cells as its first cultured meat product. It demonstrated a prototype last year. Culturing rabbit meat for dog food is next. It is a more natural diet for them that is more compatible with their digestion, says Falconer.

Wild Earth, a San Francisco Bay Area-based startup, also set out culturing mouse meat for cats but changed course after its market research showed many pet owners were alarmed by the prospect and didnt understand the concept. They thought we were killing mice and putting them into cans, says Ryan Bethencourt, co-founder and CEO. (Jokingly, Bethencourt codenamed the would-be product Jerry, inspired by Tom and Jerry cartoons.) It is now working on growing chicken and fish for dogs and cats instead. The vision is for a premium raw product in the first instance, appealing to those who feed conventional raw meat to their animals.

Bethencourt wonders whether pet food might be a gateway for cultured meat. People have shown greater willingness to be innovative with pet food, he says, citing the popularity of cricket treats for dogs. Pet food isnt so steeped in taste and tradition. The biggest market driver is expected to be pet owners wanting to avoid contaminants such as euthanasia drugs, which can get into pet food in the animal flesh that goes into the ingredients.

But cultured meat is not likely to be approved for pet food ahead of human food pet food regulators take their cues from human-food regulators. Meanwhile the industry has some advantages. Creating texture or perfecting taste is less important. And people are used to pet food being a blend of different ingredients. Percentages of cultured meat also dont have to be as high. Financially its going to be more feasible to be a pet food company, says Falconer.

Read the original:

Out of the lab and into your frying pan: the advance of cultured meat - The Guardian

Stem Cell Therapy Market is Anticipated to Attain a Market Value of US$XX by the End of 2017 2025 – Fusion Science Academy

Global Ultra-High Molecular Weight Polyethylene Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of 5.73% during forecast period.

Major driver of the global ultra-high molecular weight polyethylene market are increasing quality medical services and infrastructure, increasing surgical procedures, and growth in some diseases like osteoarthritis. Medical-grade global ultra-high molecular weight polyethylene market is a subset of polyethylene which has no taste and color. This material holds superior corrosive and abrasive resistance, lightweight, and has high strength and low coefficient of friction. These characteristics have led the medical-grade global ultra-high molecular weight polyethylene market to find extensive usage in medical usage.

Rising geriatric population is driving medical industry which in turn estimated to fuel the growth of global medical grade ultra-high molecular weight polyethylene market over the forecast period. UHMWPE is used over other materials because of its self-lubricating and low absorption properties. The UHMWPE has outstanding chemical resistance, electrically insulating and superior dielectric properties, excellent sound dampening characteristics, because of which it is used in orthopedic industry. Like an increasing demand from the orthopedic industry is expected to drive the growth of the medical grade global ultra-high molecular weight polyethylene market over the forecast period.

Primary application of UHMWPE includes shoulder, hip, knee, small joint and ankle replacement. Growth in joint infection, arthritis, and implant loosening have resulted in the rise of knee replacement and related surgeries. Superior properties and high versatility of UHMWPE are supposed to drive its use in knee replacement surgeries. The overall growth in replacement surgeries is estimated to propel the growth of the medical grade global ultra-high molecular weight polyethylene (UHMWPE) market over the forecast period

REQUEST inquiry FOR Before Buying REPORT:https://www.maximizemarketresearch.com/inquiry-before-buying/33150/

On the basis of form segment, the sheets segment is expected to hold largest market share during the forecast period. This large share is mainly attributed to extensive use of UHMW PE sheets in the mechanical equipment industry. The segment is also expected to grow at a higher CAGR during the forecast period, because of the increasing demand from healthcare & medical end-use industry.

Based on end-use industry segment, major end-use industries of the UHMW PE market are aerospace, healthcare & medical, defense, & shipping, mechanical equipment, and others, which include sports & lifestyle and electronics industries. Global ultra-high molecular weight polyethylene market is a simple linear background polyethylene possessing unique properties such as noise resistance, low coefficient of friction, excellent chemical resistance, self-lubrication, bio-compatible, wear resistance, and electric insulation resistance. This makes the material a preferred choice for prosthetic implant manufacturers across the globe. The healthcare end-use industry segment is estimated to grow at the highest CAGR during the forecast period. This growth is mainly attributed to increase usage of UHMW PE to manufacture orthopedic implants.

In terms of region, Asia-Pacific UHMW PE market is expected to grow at highest CAGR during the forecast period, because of the increasing demand for medical devices from countries, like China, Japan, and India.

This report studies the global ultra-high molecular weight polyethylene market size by players, regions, product types and end industries, history data. This report also studies the global market competition landscape, opportunities and challenges, market drivers and trends, sales channels, risks and entry barriers, distributors and Porters five forces analysis.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding global ultra-high molecular weight polyethylene market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the modest analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTERs analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in global ultra-high molecular weight polyethylene market.

Do REQUEST Sample Report Here:https://www.maximizemarketresearch.com/request-sample/33150/#inquiry

Scope of the Global Ultra-High Molecular Weight Polyethylene Market

Global Ultra-High Molecular Weight Polyethylene Market, By Form

Sheets Rods & Tubes OthersGlobal Ultra-High Molecular Weight Polyethylene Market, By End-Use Industry

Healthcare & Medical Aerospace, Defense, and Shipping Mechanical Equipment OthersGlobal Ultra-High Molecular Weight Polyethylene Market, By Region

North America Europe Asia Pacific Middle East and Africa South AmericaKey players operating in Global Ultra-High Molecular Weight Polyethylene Market

Braskem S.A. Celanese Corporation Lyondellbasell Industries N.V. Koninklijke DSM N.V. Asahi Kasei Corporation Mitsui Chemicals, Inc. Saudi Basic Industries Corporation E. I. Du Pont De Nemours and Company Honeywell International Inc. Toyobo Co., Limited Teijin Limited Rochling Engineering Plastics Pvt. Ltd. Quadrant Engineering Plastic Products Crown Plastics Company, Inc Redwood Plastics King Plastic Corporation Garland Manufacturing Company Korea Petrochemical Ind. Co., Ltd Orthoplastics CP Medical, Inc. EMCO Industrial Plastics, Inc. Global Polymers Shanghai Lianle Chemical Industry Science and Technology Co. Ltd Nitto Denko Corporation Shandong Ningjin Xinxing Chemical Co., Ltd.

Browse Full Report with Facts and Figures of Ultra-High Molecular Weight Polyethylene Market Report at:https://www.maximizemarketresearch.com/market-report/global-ultra-high-molecular-weight-polyethylene-market/33150/

MAJOR TOC OF THE REPORT

Chapter One: Ultra-High Molecular Weight Polyethylene Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Ultra-High Molecular Weight Polyethylene Market Competition, by Players

Chapter Four: Global Ultra-High Molecular Weight Polyethylene Market Size by Regions

Chapter Five: North America Ultra-High Molecular Weight Polyethylene Revenue by Countries

Chapter Six: Europe Ultra-High Molecular Weight Polyethylene Revenue by Countries

Chapter Seven: Asia-Pacific Ultra-High Molecular Weight Polyethylene Revenue by Countries

Chapter Eight: South America Ultra-High Molecular Weight Polyethylene Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Ultra-High Molecular Weight Polyethylene by Countries

Chapter Ten: Global Ultra-High Molecular Weight Polyethylene Market Segment by Type

Chapter Eleven: Global Ultra-High Molecular Weight Polyethylene Market Segment by Application

Chapter Twelve: Global Ultra-High Molecular Weight Polyethylene Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read the original here:

Stem Cell Therapy Market is Anticipated to Attain a Market Value of US$XX by the End of 2017 2025 - Fusion Science Academy

AgeX Therapeutics Announces Drawdown of Second Tranche of Loan Facility from Juvenescence Ltd. – BioSpace

Juvenescence is pleased to continue its commitment to AgeX through this additional drawdown under the loan facility, commented Gregory Bailey, MD, Chairman of AgeX and CEO of Juvenescence. Juvenescence remains committed to funding the future development plans of AgeX through further advancements under the loan facility or otherwise. Since Juvenescences initial investment in AgeX in June 2018, AgeX has been an important element in the Juvenescence mission and strategy. Juvenescence is also investing its time and personnel to support AgeXs business development initiatives which have impressive potential. We look forward to AgeX announcing its plans for 2020 as it pursues tissue regeneration in Reverse Bioengineering, while advancing the development of BAT and VASC 1, the coupling of HLA-G with PureStem-derived cells for transplant therapies, and exploring partnerships with third parties.

This round of funding will allow us to continue to execute on our strategic plan to provide therapies for certain chronic and degenerative diseases through cellular regeneration and replacement, commented AgeXs founder and CEO Michael D. West, PhD.

As announced in the companys news release on August 14, 2019, AgeX has obtained a $2 million credit facility from Juvenescence to finance AgeXs operations and advance its product development programs.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191226005045/en/

See the original post here:

AgeX Therapeutics Announces Drawdown of Second Tranche of Loan Facility from Juvenescence Ltd. - BioSpace

Stem Cell Therapy Market Consumer Outlook 2025 | MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. – Market Research Sheets

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

To know Untapped Opportunities in the MarketCLICK HERE NOW

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Get Discount on Latest Report @CLICK HERE NOW

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

This post was originally published on Market Research Sheets

See the original post here:

Stem Cell Therapy Market Consumer Outlook 2025 | MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. - Market Research Sheets

The Next Generation of Biologic Pacemakers? New Discovery in Stem Cells from Fat Creates Another Alternative Treatment – DocWire News

A research team from the University of Houston has found a way to use the stem cells found in fat and guide it to become a pacemaker-like cell, according to a new study.

We are reprogramming the cardiac progenitor cell and guiding it to become a conducting cell of the heart to conduct electrical current, said study co-author Bradley McConnell, associate professor of pharmacology, in a press release

The team, publishing the study in the Journal of Molecular and Cellular Cardiology, worked on converting adipogenic mesenchymal stem cells, which reside within fat cells, into cardia progenitor cells. The ensuing cardiac progenitor cells can be programmed to aid heartbeats as a sinoatrial node (SAN), which is part of the electrical cardiac conduction system.

The researchers used what they called a standard screening strategy to test for reprogramming factors for converting human cardiac progenitor cells into pacemaker-like cells. According to their study results, the authors observed expressions of many pacemaker-specific genes, including CX30.2, KCNN4, HCN4, HCN3, HCN1, and SCN3b. The authors wrote that SHOX2, HCN2, and TBX5 (SHT5) combinations of transcription factors were much better candidate(s) in driving cardiac progenitor cells into pacemaker-like cells than other combinations and single transcription factors.

Results of this study show that the SHT5 combination of transcription factors can reprogram CPCs into Pacemaker-like cells, they wrote in their conclusion. SHT5 may be used as a potential stem cell therapy for sick sinus syndrome (SSS) and for other cardiac conduction diseases.

Continue reading here:

The Next Generation of Biologic Pacemakers? New Discovery in Stem Cells from Fat Creates Another Alternative Treatment - DocWire News